-

Orthofix Announces Changes to Board of Directors

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik has been re-appointed as the Chair of the Company’s Board of Directors. Additionally, shareholders re-elected Wayne Burris who previously served on the Orthofix board from 2021-2022. Burris will serve on the Audit and Finance and Compliance and Ethics Committees. As previously announced Jon Serbousek, who served as Executive Chairman of the Board, did not stand for re-election at the annual shareholders meeting held yesterday.

Burzik previously served as the Company’s Chair of the Board from 2021-2022 before assuming the position of Lead Independent Director of the new combined board that was formed following the merger of SeaSpine and Orthofix.

“I am honored to step back into the role of Chair for Orthofix,” said Catherine Burzik. “I would like to thank Jon for his leadership and commitment to the company and the merger integration. I am grateful for the counsel he provided as both the Chief Executive Officer of Orthofix and as the Executive Chairman of the board and we wish him the best as he continues his work to advance the medical device industry.” Burzik continued, “I am also pleased to welcome back Wayne Burris whose dedication and strong background in accounting and finance will help guide us to long-term success.”

“I am delighted to rejoin the Orthofix Board of Directors,” said Wayne Burris. “I look forward to working with Keith Valentine and his leadership team to drive collaboration as the new merged company strives to be the partner of choice for our surgeon customers.”

Prior to joining the Orthofix Board of Directors, Burzik served as President and Chief Executive Officer of Kinetic Concepts, Inc., a global medical device company, from 2006 until the company’s sale in 2011. Prior to that, she served as President of Applied Biosystems Group and held senior executive positions at Eastman Kodak Health Imaging Systems and President of Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company.

Burris served as the Senior Vice President and Chief Financial Officer (CFO) at Roche Diagnostics Corporation from 1996 through his retirement in July 2019. A member of the Global Roche Diagnostics Finance Executive Committee, Burris was recognized as one of their top senior leaders.

About Orthofix

The newly merged Orthofix-SeaSpine organization is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions and a leading surgical navigation system. Its products are distributed in more than 68 countries worldwide.

The Company is headquartered in Lewisville, Texas and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France, and São Paulo, Brazil.

Contacts

Media Relations
Denise Landry
DeniseLandry@orthofix.com
214.937.2529

Investor Relations
Louisa Smith, Gilmartin Group
IR@orthofix.com

Orthofix Medical Inc.

NASDAQ:OFIX

Release Versions

Contacts

Media Relations
Denise Landry
DeniseLandry@orthofix.com
214.937.2529

Investor Relations
Louisa Smith, Gilmartin Group
IR@orthofix.com

Social Media Profiles
More News From Orthofix Medical Inc.

Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers. “I have b...

Orthofix Reports First Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6-C™ and M6-L™ artificial disc product...

Orthofix to Report First Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the...
Back to Newsroom